37.78 USD
-1.34 (-3.43%)
37.9859 USD
+0.21 (+0.54%)
We assign a fundamental rating of 7 out of 10 to RIGL. RIGL was compared to 528 industry peers in the Biotechnology industry. RIGL has an excellent financial health rating, but there are some minor concerns on its profitability. RIGL is growing strongly while it also seems undervalued. This is an interesting combination This makes RIGL very considerable for value and growth investing!
1. Profitability
1.1 Basic Checks
- In the past year RIGL was profitable.
- RIGL had a positive operating cash flow in the past year.
- In the past 5 years RIGL reported 4 times negative net income.
- The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
1.2 Ratios
- RIGL has a better Return On Assets (46.72%) than 99.43% of its industry peers.
- Looking at the Return On Equity, with a value of 96.34%, RIGL belongs to the top of the industry, outperforming 99.43% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 63.44%, RIGL belongs to the top of the industry, outperforming 99.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROIC | 63.44% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- RIGL has a better Profit Margin (40.17%) than 96.78% of its industry peers.
- RIGL has a Operating Margin of 42.17%. This is amongst the best in the industry. RIGL outperforms 98.67% of its industry peers.
- RIGL has a better Gross Margin (93.10%) than 93.75% of its industry peers.
- In the last couple of years the Gross Margin of RIGL has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RIGL is creating value.
- Compared to 1 year ago, RIGL has more shares outstanding
- The number of shares outstanding for RIGL has been reduced compared to 5 years ago.
- The debt/assets ratio for RIGL has been reduced compared to a year ago.
2.2 Solvency
- RIGL has an Altman-Z score of -0.66. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
- RIGL's Altman-Z score of -0.66 is in line compared to the rest of the industry. RIGL outperforms 57.77% of its industry peers.
- The Debt to FCF ratio of RIGL is 0.88, which is an excellent value as it means it would take RIGL, only 0.88 years of fcf income to pay off all of its debts.
- With an excellent Debt to FCF ratio value of 0.88, RIGL belongs to the best of the industry, outperforming 93.94% of the companies in the same industry.
- A Debt/Equity ratio of 0.25 indicates that RIGL is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.25, RIGL is not doing good in the industry: 66.10% of the companies in the same industry are doing better.
- Although RIGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Altman-Z | -0.66 |
ROIC/WACC7.14
WACC8.89%
2.3 Liquidity
- RIGL has a Current Ratio of 2.28. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of RIGL (2.28) is worse than 72.92% of its industry peers.
- A Quick Ratio of 2.14 indicates that RIGL has no problem at all paying its short term obligations.
- RIGL has a Quick ratio of 2.14. This is in the lower half of the industry: RIGL underperforms 72.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 4307.14% over the past year.
- RIGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 79.13%.
- RIGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.77% yearly.
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
3.2 Future
- Based on estimates for the next years, RIGL will show a very strong growth in Earnings Per Share. The EPS will grow by 45.43% on average per year.
- Based on estimates for the next years, RIGL will show a quite strong growth in Revenue. The Revenue will grow by 15.70% on average per year.
EPS Next Y611.29%
EPS Next 2Y116.3%
EPS Next 3Y80.91%
EPS Next 5Y45.43%
Revenue Next Year67.77%
Revenue Next 2Y29.67%
Revenue Next 3Y25.83%
Revenue Next 5Y15.7%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- RIGL is valuated cheaply with a Price/Earnings ratio of 6.12.
- Based on the Price/Earnings ratio, RIGL is valued cheaply inside the industry as 98.86% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 27.54. RIGL is valued rather cheaply when compared to this.
- The Price/Forward Earnings ratio is 8.59, which indicates a very decent valuation of RIGL.
- Based on the Price/Forward Earnings ratio, RIGL is valued cheaply inside the industry as 98.86% of the companies are valued more expensively.
- RIGL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.12 | ||
| Fwd PE | 8.59 |
4.2 Price Multiples
- RIGL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. RIGL is cheaper than 99.05% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 98.67% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.06 | ||
| EV/EBITDA | 4.48 |
4.3 Compensation for Growth
- RIGL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- RIGL has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as RIGL's earnings are expected to grow with 80.91% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y116.3%
EPS Next 3Y80.91%
5. Dividend
5.1 Amount
- No dividends for RIGL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
37.78
-1.34 (-3.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners85.11%
Inst Owner Change-0.09%
Ins Owners2.59%
Ins Owner Change0%
Market Cap685.71M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Analysts80
Price Target46.24 (22.39%)
Short Float %15.98%
Short Ratio4.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)0%
PT rev (3m)18.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.6%
EPS NY rev (1m)0%
EPS NY rev (3m)17.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.12 | ||
| Fwd PE | 8.59 | ||
| P/S | 2.43 | ||
| P/FCF | 10.06 | ||
| P/OCF | 10.06 | ||
| P/B | 5.83 | ||
| P/tB | 7.43 | ||
| EV/EBITDA | 4.48 |
EPS(TTM)6.17
EY16.33%
EPS(NY)4.4
Fwd EY11.64%
FCF(TTM)3.75
FCFY9.94%
OCF(TTM)3.76
OCFY9.94%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)0.01
PEG (5Y)N/A
Graham Number29.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROCE | 80.3% | ||
| ROIC | 63.44% | ||
| ROICexc | 854.98% | ||
| ROICexgc | N/A | ||
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% | ||
| FCFM | 24.16% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 1.57% | ||
| Cap/Sales | 0.01% | ||
| Interest Coverage | 17.61 | ||
| Cash Conversion | 56.17% | ||
| Profit Quality | 60.14% | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 | ||
| Altman-Z | -0.66 |
F-Score7
WACC8.89%
ROIC/WACC7.14
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y611.29%
EPS Next 2Y116.3%
EPS Next 3Y80.91%
EPS Next 5Y45.43%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year67.77%
Revenue Next 2Y29.67%
Revenue Next 3Y25.83%
Revenue Next 5Y15.7%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year525.53%
EBIT Next 3Y109.33%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 7 / 10 to RIGL.
What is the valuation status for RIGL stock?
ChartMill assigns a valuation rating of 9 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
How financially healthy is RIGEL PHARMACEUTICALS INC?
The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 7 / 10.